GADICKE ANSBERT

About GADICKE ANSBERT

Dr. Ansbert Gadicke is a senior biotechnology and oncology investor and corporate governance figure in the U.S. life sciences sector. His most visible and recent public company role is as Chairman of the Board, notably at Cullinan Therapeutics (formerly Cullinan Oncology), where he has been involved since the company’s early buildout and has helped oversee its strategic direction. Public sources also identify him as a board member or former board member across several oncology-focused biotech companies, including iTeos Therapeutics, Repare Therapeutics, Harpoon Therapeutics, and Werewolf Therapeutics; however, exact affiliations can change over time, and not every database presents them uniformly. ([theorg.com](https://theorg.com/org/orna-therapeutics/org-chart/ansbert-gadicke?utm_source=openai)) Through MPM BioImpact and related venture activities, Gadicke has played a central role in building and supporting biopharmaceutical companies. Public biographies credit him with helping build companies such as BioMarin Pharmaceuticals, Idenix Pharmaceuticals, Mitobridge, and Pharmasset, as well as more recent efforts around Cullinan, iTeos, AlloVir, ElevateBio, and Orna Therapeutics. His profile reflects a combination of scientific judgment, company formation experience, and board-level oversight. In practical terms, that has meant helping finance new platforms, supporting executive and board composition, guiding strategic capital allocation, and shaping decisions around clinical development and value creation in oncology and precision medicine. ([theorg.com](https://theorg.com/org/mpm-capital/org-chart/ansbert-gadicke?utm_source=openai)) Scientifically, public biographies describe him as a physician who worked at the German Cancer Research Center in Professor Harald zur Hausen’s group, with a research focus on HPV16 and HPV18. That background helps explain his long-standing concentration on oncology and advanced therapeutics. From a governance perspective, he is associated with long-horizon strategic decisions: backing differentiated science, helping companies move through key development milestones, and providing oversight for both private and public biopharmaceutical ventures. Because some public profiles vary in how they describe his current titles and board seats, the wording here stays intentionally conservative and avoids over-specifying any affiliation that may have changed. ([theorg.com](https://theorg.com/org/orna-therapeutics/org-chart/ansbert-gadicke?utm_source=openai))